Fulcrum Therapeutics appoints Sonja L. Banks to board of directors

Fulcrum Therapeutics, Inc.

Sonja Banks elected as Class I director, effective December 8, 2021, with term expiring at 2023 annual meeting.
Banks is CEO of International Dyslexia Association and former president of Sickle Cell Disease Association of America.
Her election expands the board to nine members; she is deemed independent under Nasdaq rules.
Banks will receive standard non-employee director compensation including a one-time option to purchase 30,000 shares.
Fulcrum focuses on rare genetic diseases; Banks brings ~25 years of patient advocacy and nonprofit leadership experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sonja Banks

Director

FULC · Fulcrum Therapeutics, Inc.

Effective: 2021-12-08
Filed: November 17, 2021, 6:59 PM ET

elected Sonja Banks as a member of the Board, effective December 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sonja Banks was elected as Director at Fulcrum Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

elected Sonja Banks as a member of the Board, effective December 8, 2021.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-331947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.